摘要
背景与目的:程序性死亡[蛋白]-1(programmed death-1,PD-1)单抗免疫治疗在头颈部鳞状细胞癌(head and neck squamous cell carcinoma,HNSCC)中的作用愈发重要,然而目前具有响应率低、缺乏预测性生物标志物的问题。本研究旨在确定程序性死亡[蛋白]配体-2(programmed death ligand-2,PD-L2)能否作为预测HNSCC中PD-1单抗免疫治疗获益情况的生物标志物。方法:收集50例接受PD-1单克隆抗体免疫治疗的中晚期HNSCC的组织标本及临床数据,采用免疫组织化学染色法分析程序性死亡[蛋白]配体-1(programmed death ligand-1,PD-L1)、PD-L2表达量,采用SPSS 26.0软件根据基本临床特征、PD-L1与PD-L2表达量分组统计并进行Kaplan-Meier生存分析,采用GraphPad Prism软件绘制生存曲线。结果:PD-L2在HNSCC患者中阳性表达率较高,有超过80%的患者肿瘤组织可检出PD-L2表达;PD-L2的表达量显著影响免疫治疗结局,PD-L2高表达的患者平均生存期为18.8(16.0~21.7)个月,而PD-L2低表达的患者平均生存期为11.0(9.1~12.8)个月,差异有统计学意义(P<0.05)。结论:PD-L2可作为评估HNSCC中PD-1单克隆抗体免疫治疗获益的生物标志物。
Background and purpose:Programmed death-1(PD-1)monoclonal antibody therapy plays an increasingly important role in the treatment of head and neck squamous cell carcinoma(HNSCC).However,low response rate and lack of predictive biomarkers are still the challenging problems.This study aimed to confirm that programmed death ligand-2(PD-L2)is a predictive biomarker for the outcome of HNSCC anti-PD-1 immunotherapy.Methods:The samples and clinical data of 50 HNSCC patients undergoing PD-1 monoclonal antibody immunotherapy were collected.Immunohistochemical staining was used to analyze the level of programmed death ligand-1(PD-L1)and PD-L2.Kaplan-Meier overall survivals were analyzed using SPSS 26.0 software,grouped by the basic clinical characteristics and the PD-L1 and PD-L2 levels.Survival curves were plotted using GraphPad Prism.Results:HNSCC had a relatively high expression rate of PD-L2 with more than 80%of cases detected as PD-L2 positive.The expression of PD-L2 significantly correlated with the clinical outcome of immunotherapy,with a mean survival of 18.8(16.0-21.7)months for patients with high PD-L2 expression and 11.0(9.1-12.8)months for patients with low PD-L2 expression,this difference being statistically significant.Conclusion:PD-L2 has the potential to be used as a predictive biomarker for HNSCC anti-PD-1 immunotherapy.
作者
黄鹤
鞠侯雨
杨文艺
严明
任国欣
胡镜宙
HUANG He;JU Houyu;YANG Wenyi;YAN Ming;REN Guoxin;HU Jingzhou(Department of Oral&Maxillofacial-Head&Neck Oncology,Shanghai Ninth People’s Hospital,Shanghai Jiao Tong University School of Medicine,College of Stomatology,Shanghai Jiao Tong University,National Center for Stomatology,National Clinical Research Center for Oral Diseases,Shanghai Key Laboratory of Stomatology,Shanghai Research Institute of Stomatology,Shanghai 200011,China)
出处
《中国癌症杂志》
CAS
CSCD
北大核心
2023年第6期613-618,共6页
China Oncology
关键词
头颈部鳞状细胞癌
免疫治疗
PD-L2
PD-1单克隆抗体
Head and neck squamous cell carcinoma
Immunotherapy
Programmed death ligand-2
Programmed death-1 monoclonal antibody
